Mercer Global Advisors
MLYS icon

Mercer Global Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Mercer Global Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164K Buy
+6,077
New +$167K ﹤0.01% 3423

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM

Mercer Global Advisors's MLYS Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 6,077 shares worth $164K. The stake represents ﹤0.01% of the portfolio and ranks #3423 among its holdings.

201 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Mercer Global Advisors held 6,077 shares of Mineralys Therapeutics worth $164K as of Q2 2026.
  • Mineralys Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3423 holding.
  • 201 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.